ATE353889T1 - Rho-kinase inhibitoren - Google Patents
Rho-kinase inhibitorenInfo
- Publication number
- ATE353889T1 ATE353889T1 AT02713884T AT02713884T ATE353889T1 AT E353889 T1 ATE353889 T1 AT E353889T1 AT 02713884 T AT02713884 T AT 02713884T AT 02713884 T AT02713884 T AT 02713884T AT E353889 T1 ATE353889 T1 AT E353889T1
- Authority
- AT
- Austria
- Prior art keywords
- kinase inhibitors
- rho kinase
- rho
- inhibitors
- kinase
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pulmonology (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Heart & Thoracic Surgery (AREA)
- Rheumatology (AREA)
- Diabetes (AREA)
- Ophthalmology & Optometry (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Gynecology & Obstetrics (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US27797401P | 2001-03-23 | 2001-03-23 | |
| US31533801P | 2001-08-29 | 2001-08-29 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE353889T1 true ATE353889T1 (de) | 2007-03-15 |
Family
ID=26958818
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT02713884T ATE353889T1 (de) | 2001-03-23 | 2002-03-22 | Rho-kinase inhibitoren |
Country Status (18)
| Country | Link |
|---|---|
| US (3) | US20030087919A1 (de) |
| EP (1) | EP1370552B1 (de) |
| JP (1) | JP4320705B2 (de) |
| AR (1) | AR035792A1 (de) |
| AT (1) | ATE353889T1 (de) |
| AU (1) | AU2002245709A1 (de) |
| CA (1) | CA2441501C (de) |
| CY (1) | CY1108041T1 (de) |
| DE (1) | DE60218138T2 (de) |
| DK (1) | DK1370552T3 (de) |
| ES (1) | ES2280517T3 (de) |
| MX (1) | MXPA03008659A (de) |
| MY (1) | MY142915A (de) |
| PE (1) | PE20020958A1 (de) |
| PT (1) | PT1370552E (de) |
| TW (1) | TWI336328B (de) |
| UY (1) | UY27225A1 (de) |
| WO (1) | WO2002076977A2 (de) |
Families Citing this family (92)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2298311B1 (de) | 1999-01-13 | 2012-05-09 | Bayer HealthCare LLC | Omega-carboxyarylsubstituierte-Diphenyl-Harnstoffe als p38-Kinasehemmer |
| US8124630B2 (en) | 1999-01-13 | 2012-02-28 | Bayer Healthcare Llc | ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
| DK1478358T3 (da) | 2002-02-11 | 2013-10-07 | Bayer Healthcare Llc | Sorafenibtosylat til behandling af sygdomme kendetegnet ved unormal angiogenese |
| US7645878B2 (en) * | 2002-03-22 | 2010-01-12 | Bayer Healthcare Llc | Process for preparing quinazoline Rho-kinase inhibitors and intermediates thereof |
| KR101160780B1 (ko) | 2002-08-29 | 2012-06-27 | 산텐 세이야꾸 가부시키가이샤 | Rho 키나아제 억제제 및 프로스타글란딘류를 포함하는 녹내장 치료제 |
| GB0307333D0 (en) * | 2003-03-29 | 2003-05-07 | Astrazeneca Ab | Therapeutic agent |
| KR101076638B1 (ko) * | 2003-04-18 | 2011-10-27 | 센주 세이야꾸 가부시키가이샤 | 각막 지각 회복제 |
| EP1636585B2 (de) | 2003-05-20 | 2012-06-13 | Bayer HealthCare LLC | Diaryl-harnstoffe mit kinasehemmender wirkung |
| PL1663978T3 (pl) | 2003-07-23 | 2008-04-30 | Bayer Healthcare Llc | Fluoropodstawiony omega-karboksyarylodifenylomocznik do leczenia i profilaktyki chorób i stanów |
| TWI344961B (en) | 2003-10-15 | 2011-07-11 | Ube Industries | Novel indazole derivative |
| DE602006017188D1 (de) | 2005-03-07 | 2010-11-11 | Bayer Schering Pharma Ag | Pharmazeutische zusammensetzung mit einem omega-carboxyaryl-substituierten diphenylharnstoff zur behandlung von krebs |
| CR9465A (es) * | 2005-03-25 | 2008-06-19 | Surface Logix Inc | Compuestos mejorados farmacocineticamente |
| AU2006285915B2 (en) | 2005-08-30 | 2011-02-24 | Asahi Kasei Pharma Corporation | Sulfonamide compound |
| JPWO2007142323A1 (ja) | 2006-06-08 | 2009-10-29 | 宇部興産株式会社 | 側鎖にスピロ環構造を有する新規インダゾール誘導体 |
| CA2700988A1 (en) * | 2006-09-27 | 2008-05-08 | Surface Logix, Inc. | Rho kinase inhibitors |
| JP5208123B2 (ja) * | 2006-12-08 | 2013-06-12 | アイアールエム・リミテッド・ライアビリティ・カンパニー | タンパク質キナーゼ阻害剤としての化合物および組成物 |
| EA019941B1 (ru) | 2006-12-08 | 2014-07-30 | АйАрЭм ЭлЭлСи | Соединения и композиции в качестве ингибиторов протеинкиназы |
| US8415372B2 (en) | 2007-02-27 | 2013-04-09 | Asahi Kasei Pharma Corporation | Sulfonamide compound |
| CA2679263A1 (en) | 2007-02-28 | 2008-09-04 | Asahi Kasei Pharma Corporation | Sulfonamide compound |
| WO2009004792A1 (ja) | 2007-07-02 | 2009-01-08 | Asahi Kasei Pharma Corporation | スルホンアミド化合物及びその結晶 |
| KR20240045364A (ko) | 2007-08-29 | 2024-04-05 | 센주 세이야꾸 가부시키가이샤 | 각막 내피 세포 접착 촉진제 |
| ES2849181T3 (es) | 2009-04-22 | 2021-08-16 | Viacyte Inc | Composiciones celulares derivadas de células reprogramadas desdiferenciadas |
| US9109245B2 (en) | 2009-04-22 | 2015-08-18 | Viacyte, Inc. | Cell compositions derived from dedifferentiated reprogrammed cells |
| MX389666B (es) | 2009-10-16 | 2025-03-19 | Scripps Research Inst | Induccion de celulas pluripotentes. |
| EP3255142A1 (de) | 2009-10-19 | 2017-12-13 | Cellular Dynamics International, Inc. | Herstellung von kardiomyozyten |
| CA2802249A1 (en) | 2010-06-15 | 2011-12-22 | Cellular Dynamics International, Inc. | Generation of induced pluripotent stem cells from small volumes of peripheral blood |
| US9732319B2 (en) | 2010-12-22 | 2017-08-15 | Fate Therapeutics, Inc. | Cell culture platform for single cell sorting and enhanced reprogramming of iPSCs |
| JP6026441B2 (ja) | 2011-03-04 | 2016-11-16 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドGlaxosmithkline Intellectual Property Development Limited | キナーゼ阻害剤としてのアミノキノリン |
| CA2831609C (en) | 2011-03-30 | 2019-06-11 | Cellular Dynamics International, Inc. | Priming of pluripotent stem cells for neural differentiation |
| WO2013009825A1 (en) | 2011-07-11 | 2013-01-17 | Cellular Dynamics International, Inc. | Methods for cell reprogramming and genome engineering |
| TWI547494B (zh) | 2011-08-18 | 2016-09-01 | 葛蘭素史克智慧財產發展有限公司 | 作為激酶抑制劑之胺基喹唑啉類 |
| TR201903889T4 (tr) | 2011-12-06 | 2019-04-22 | Astellas Inst For Regenerative Medicine | Korneal endotelyal hücreler üreten yönlendirilmiş diferansiyasyona yönelik yöntem. |
| US20150044178A1 (en) | 2011-12-28 | 2015-02-12 | Kyoto Prefectural Public University Corporation | Normalization of culture of corneal endothelial cells |
| EP2628482A1 (de) | 2012-02-17 | 2013-08-21 | Academisch Medisch Centrum | Rho Kinase Inhibitoren in der Verwendung zur Behandlung von Neuroblastoma |
| EP2826855B1 (de) | 2012-03-15 | 2018-08-29 | iHeart Japan Corporation | Myocardiale zellschicht |
| US9334475B2 (en) | 2012-04-06 | 2016-05-10 | Kyoto University | Method for inducing erythropoietin-producing cell |
| AR092529A1 (es) | 2012-09-13 | 2015-04-22 | Glaxosmithkline Llc | Compuesto de aminoquinazolina, composicion farmaceutica que lo comprende y uso de dicho compuesto para la preparacion de un medicamento |
| CN105143208B (zh) | 2013-02-21 | 2017-09-26 | 葛兰素史密斯克莱知识产权发展有限公司 | 作为激酶抑制剂的喹唑啉 |
| US8859286B2 (en) | 2013-03-14 | 2014-10-14 | Viacyte, Inc. | In vitro differentiation of pluripotent stem cells to pancreatic endoderm cells (PEC) and endocrine cells |
| WO2014165663A1 (en) | 2013-04-03 | 2014-10-09 | Cellular Dynamics International, Inc. | Methods and compositions for culturing endoderm progenitor cells in suspension |
| JP6461787B2 (ja) | 2013-04-12 | 2019-01-30 | 国立大学法人京都大学 | 肺胞上皮前駆細胞の誘導方法 |
| MX2015017036A (es) | 2013-06-11 | 2016-07-21 | Univ Kyoto | Metodo para producir celulas progenitoras renales y farmaco que comprende las mismas. |
| US10908161B2 (en) | 2013-07-30 | 2021-02-02 | Kyoto Prefectural Public University Corporation | Corneal endothelial cell marker |
| JP6378183B2 (ja) | 2013-08-07 | 2018-08-22 | 国立大学法人京都大学 | 膵ホルモン産生細胞の製造法 |
| CN121136933A (zh) | 2013-09-05 | 2025-12-16 | 国立大学法人京都大学 | 由多能干细胞制造产多巴胺神经前体细胞的方法、产多巴胺神经前体细胞、帕金森病治疗剂和试剂盒 |
| CA2927898C (en) | 2013-10-31 | 2021-11-16 | Kyoto Prefectural Public University Corporation | Therapeutic drug for diseases related to endoplasmic reticulum cell death in corneal endothelium |
| BR112016011096A2 (pt) | 2013-11-27 | 2017-09-19 | Kyoto Prefectural Public Univ Corp | Aplicação de laminina à cultura de célula endotelial da córnea |
| CN120536341A (zh) | 2014-03-04 | 2025-08-26 | 菲特治疗公司 | 改良的重编程方法和细胞培养平台 |
| CN106536718B (zh) | 2014-05-21 | 2021-04-27 | 国立大学法人京都大学 | 胰芽细胞的制造方法及含有胰芽细胞的胰疾病治疗剂 |
| US10711249B2 (en) | 2014-12-26 | 2020-07-14 | Kyoto University | Method for inducing hepatocytes |
| CN117737124A (zh) | 2015-10-16 | 2024-03-22 | 菲特治疗公司 | 用于诱导和维护基态多能性的平台 |
| KR102929174B1 (ko) | 2015-10-30 | 2026-02-20 | 더 리전츠 오브 더 유니버시티 오브 캘리포니아 | 줄기세포로부터 t-세포를 생산하는 방법 및 상기 t-세포를 이용한 면역치료 방법 |
| EP3416658B1 (de) | 2016-02-15 | 2023-03-22 | Kyoto Prefectural Public University Corporation | Menschliche funktionelle hornhautendothelzelle und anwendung davon |
| JPWO2017150174A1 (ja) * | 2016-03-04 | 2019-06-13 | 株式会社 シンスター・ジャパン | 2,4−ジアミノキナゾリン誘導体又はその塩を有効成分として含有する医薬品組成物、及び、特定の構造を有する2,4−ジアミノキナゾリン誘導体 |
| EP3447130A4 (de) | 2016-04-22 | 2019-11-13 | Kyoto University | Verfahren zur herstellung von dopaminproduzierenden neuralen vorläuferzellen |
| AU2017313065B2 (en) | 2016-08-16 | 2021-06-24 | Fujifilm Cellular Dynamics Inc. | Methods for differentiating pluripotent cells |
| WO2018216743A1 (ja) | 2017-05-25 | 2018-11-29 | 国立大学法人京都大学 | 中間中胚葉細胞から腎前駆細胞への分化誘導方法、および多能性幹細胞から腎前駆細胞への分化誘導方法 |
| AU2018364852B2 (en) | 2017-11-10 | 2022-06-30 | Regenesis Science Co., Ltd. | Method for producing cultured cell, and method for producing therapeutic agent for spinal cord injury disease |
| CA3082643A1 (en) | 2017-11-14 | 2019-05-23 | The Schepens Eye Research Institute, Inc. | Runx1 inhibition for treatment of proliferative vitreoretinopathy and conditions associated with epithelial to mesenchymal transition |
| EP3730138B1 (de) | 2017-12-21 | 2024-02-14 | Santen Pharmaceutical Co., Ltd. | Kombination von sepetaprost und ripasudil zur verwendung in der prophylaxe oder behandlung von glaukom oder okulärer hypertension |
| CN111527197A (zh) | 2017-12-28 | 2020-08-11 | 株式会社钟化 | 细胞聚集促进剂 |
| CN111788300B (zh) | 2017-12-28 | 2024-08-13 | 株式会社钟化 | 细胞聚集抑制剂 |
| JP7336386B2 (ja) | 2017-12-28 | 2023-08-31 | 株式会社カネカ | 多能性幹細胞凝集抑制剤 |
| CA3096870A1 (en) | 2018-02-19 | 2019-08-22 | Sumitomo Dainippon Pharma Co., Ltd. | Cell aggregate, mixture of cell aggregates, and method for preparing same |
| WO2020022261A1 (ja) | 2018-07-23 | 2020-01-30 | 国立大学法人京都大学 | 新規腎前駆細胞マーカーおよびそれを利用した腎前駆細胞の濃縮方法 |
| CA3110661A1 (en) | 2018-08-29 | 2020-03-05 | University Of Massachusetts | Inhibition of protein kinases to treat friedreich ataxia |
| JPWO2020045642A1 (ja) | 2018-08-31 | 2021-08-12 | 学校法人同志社 | 眼細胞を保存または培養するための組成物および方法 |
| CN113015429A (zh) | 2018-10-02 | 2021-06-22 | 学校法人同志社 | 用于保存角膜内皮细胞的方法和容器 |
| WO2020130147A1 (ja) | 2018-12-21 | 2020-06-25 | 国立大学法人京都大学 | ルブリシン局在軟骨様組織、その製造方法及びそれを含む関節軟骨損傷治療用組成物 |
| WO2020193802A1 (en) | 2019-03-28 | 2020-10-01 | Fundación De La Comunidad Valenciana Centro De Investigación Príncipe Felipe | Polymeric conjugates and uses thereof |
| JP7489377B2 (ja) | 2019-03-29 | 2024-05-23 | 株式会社カネカ | 多能性幹細胞を含む細胞集団及びその製造方法 |
| WO2020230832A1 (ja) | 2019-05-15 | 2020-11-19 | 味の素株式会社 | 神経堤細胞または角膜上皮細胞の純化方法 |
| US20230257700A1 (en) | 2020-02-27 | 2023-08-17 | Kyoto Prefectural Public University Corporation | Functional human corneal endothelial cells and application thereof |
| EP4234682A4 (de) | 2020-10-22 | 2024-11-27 | Kyoto Prefectural Public University Corporation | Konservierungsverfahren für menschliche hornhautendothelzellen und/oder menschliche hornhautendothelvorläuferzellen |
| US20240010989A1 (en) | 2021-01-08 | 2024-01-11 | Kyoto University | Medium for culturing and expanding nephron progenitor cells, method for culturing and expanding nephron progenitor cells, and method for producing renal organoids |
| CA3207859A1 (en) | 2021-01-11 | 2022-07-14 | Incyte Corporation | Combination therapy comprising jak pathway inhibitor and rock inhibitor |
| EP4319876A1 (de) | 2021-04-07 | 2024-02-14 | Fujifilm Cellular Dynamics, Inc. | Dopaminerge vorläuferzellen und verfahren zur verwendung |
| AU2022270611A1 (en) | 2021-05-03 | 2023-10-12 | Astellas Institute For Regenerative Medicine | Methods of generating mature corneal endothelial cells |
| WO2022259721A1 (ja) | 2021-06-10 | 2022-12-15 | 味の素株式会社 | 間葉系幹細胞の製造方法 |
| EP4386083A4 (de) | 2021-08-11 | 2025-11-12 | Univ Kyoto | Verfahren zur herstellung interstitieller nierenvorläuferzellen, erythropoietinproduzierende zellen und verfahren zur herstellung reninproduzierender zellen |
| EP4402249A1 (de) | 2021-09-13 | 2024-07-24 | Fujifilm Cellular Dynamics, Inc. | Verfahren zur herstellung von gebundenen herzvorläuferzellen |
| CA3238227A1 (en) | 2021-11-11 | 2023-05-19 | The Doshisha | Cryopreservation preparation for corneal endothelial cells and method for producing said cryopreservation preparation |
| KR20240103018A (ko) | 2021-11-19 | 2024-07-03 | 고쿠리쓰 겐큐 가이하쓰 호징 리가가쿠 겐큐소 | 시트상 망막 조직의 제조 방법 |
| JPWO2023153464A1 (de) | 2022-02-09 | 2023-08-17 | ||
| CN119790139A (zh) | 2022-08-31 | 2025-04-08 | 国立大学法人京都大学 | 原始态多能干细胞的制造方法 |
| EP4596675A4 (de) | 2022-09-26 | 2026-03-11 | Univ Kyoto | Verfahren zur herstellung pankreatischer endodermzellen |
| WO2024073776A1 (en) | 2022-09-30 | 2024-04-04 | FUJIFILM Cellular Dynamics, Inc. | Methods for the production of cardiac fibroblasts |
| EP4678737A1 (de) | 2023-03-03 | 2026-01-14 | Kyoto University | Verfahren zur herstellung von vorbehandelten pluripotenten stammzellen |
| TW202444894A (zh) | 2023-03-29 | 2024-11-16 | 日商住友製藥股份有限公司 | 視網膜組織之製造方法 |
| WO2024242069A1 (ja) | 2023-05-19 | 2024-11-28 | 国立大学法人京都大学 | 神経堤細胞の製造方法 |
| WO2026128800A1 (en) | 2024-12-13 | 2026-06-18 | Aurion Biotech, Inc. | Stable corneal endothelial cell (cec) compositions and methods of use |
| US20260166089A1 (en) | 2024-12-17 | 2026-06-18 | Aurion Biotech, Inc. | Treatment of corneal endothelial disease |
Family Cites Families (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4642347A (en) * | 1985-05-21 | 1987-02-10 | American Home Products Corporation | 3(2-quinolinylalkoxy)phenols |
| US5245038A (en) * | 1987-11-06 | 1993-09-14 | Baxter Diagnostics Inc. | Fluorescent poly(arylpyridine) rare earth chelates |
| IL89029A (en) * | 1988-01-29 | 1993-01-31 | Lilly Co Eli | Fungicidal quinoline and cinnoline derivatives, compositions containing them, and fungicidal methods of using them |
| US4952567A (en) * | 1988-05-09 | 1990-08-28 | City Of Hope | Inhibition of lipogenesis |
| ATE156120T1 (de) * | 1991-02-07 | 1997-08-15 | Roussel Uclaf | Bizyklische stickstoffverbindungen, ihre herstellung, erhaltene zwischenprodukte, ihre verwendung als arzneimittel und diese enthaltende pharmazeutische zusammensetzungen |
| US6004979A (en) * | 1991-02-07 | 1999-12-21 | Hoechst Marion Roussel | Nitrogenous bicycles |
| MX9200299A (es) * | 1991-02-07 | 1992-12-01 | Roussel Uclaf | Nuevos derivados biciclicos nitrogenados, su procedimiento de preparacion los nuevos compuestos intermedios obtenidos su aplicacion como medicamentos y las composiciones farmaceuticas que los contienen. |
| US5710158A (en) * | 1991-05-10 | 1998-01-20 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase |
| US6645969B1 (en) * | 1991-05-10 | 2003-11-11 | Aventis Pharmaceuticals Inc. | Aryl and heteroaryl quinazoline compounds which inhibit CSF-1R receptor tyrosine kinase |
| US5721237A (en) * | 1991-05-10 | 1998-02-24 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Protein tyrosine kinase aryl and heteroaryl quinazoline compounds having selective inhibition of HER-2 autophosphorylation properties |
| US5245036A (en) * | 1992-05-07 | 1993-09-14 | Dowelanco | Process for the preparation of 4-phenoxyquinoline compounds |
| US5972598A (en) * | 1992-09-17 | 1999-10-26 | Board Of Trustess Of The University Of Illinois | Methods for preventing multidrug resistance in cancer cells |
| GB9323290D0 (en) * | 1992-12-10 | 1994-01-05 | Zeneca Ltd | Quinazoline derivatives |
| EP1195372A1 (de) * | 1994-04-18 | 2002-04-10 | Mitsubishi Pharma Corporation | N-Heterozyklisch substitutierte Benzamid Deriviate mit antihypertensiver Wirkung |
| US5840695A (en) * | 1994-10-07 | 1998-11-24 | Heska Corporation | Ectoparasite saliva proteins and apparatus to collect such proteins |
| GB9514265D0 (en) * | 1995-07-13 | 1995-09-13 | Wellcome Found | Hetrocyclic compounds |
| US5851545A (en) * | 1995-08-25 | 1998-12-22 | Sandoz Ltd. | Insecticidal matrix and process for preparation thereof |
| US5906819A (en) * | 1995-11-20 | 1999-05-25 | Kirin Beer Kabushiki Kaisha | Rho target protein Rho-kinase |
| DE19608653A1 (de) * | 1996-03-06 | 1997-09-11 | Thomae Gmbh Dr K | Pyrimido[5,4-d]pyrimidine, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung |
| US6391874B1 (en) * | 1996-07-13 | 2002-05-21 | Smithkline Beecham Corporation | Fused heterocyclic compounds as protein tyrosine kinase inhibitors |
| PT956865E (pt) * | 1996-08-12 | 2007-07-30 | Mitsubishi Pharma Corp | Medicamentos compreendendo inibidores da rho cinase. |
| AR012634A1 (es) * | 1997-05-02 | 2000-11-08 | Sugen Inc | Compuesto basado en quinazolina, composicion famaceutica que lo comprende, metodo para sintetizarlo, su uso, metodos de modulacion de la funcion deserina/treonina proteinaquinasa con dicho compuesto y metodo in vitro para identificar compuestos que modulan dicha funcion |
| US5885803A (en) * | 1997-06-19 | 1999-03-23 | Incyte Pharmaceuticals, Inc. | Disease associated protein kinases |
| ZA986729B (en) * | 1997-07-29 | 1999-02-02 | Warner Lambert Co | Irreversible inhibitors of tyrosine kinases |
| RS49779B (sr) * | 1998-01-12 | 2008-06-05 | Glaxo Group Limited, | Biciklična heteroaromatična jedinjenja kao inhibitori protein tirozin kinaze |
| GB9800575D0 (en) * | 1998-01-12 | 1998-03-11 | Glaxo Group Ltd | Heterocyclic compounds |
| AU5682799A (en) * | 1998-08-21 | 2000-03-14 | Parker Hughes Institute | Quinazoline derivatives |
| US6184226B1 (en) * | 1998-08-28 | 2001-02-06 | Scios Inc. | Quinazoline derivatives as inhibitors of P-38 α |
| WO2000039191A1 (de) * | 1998-12-23 | 2000-07-06 | Bayer Aktiengesellschaft | Polycarbonate mit niedrigem yellowness-index |
| GB2345486A (en) * | 1999-01-11 | 2000-07-12 | Glaxo Group Ltd | Heteroaromatic protein tyrosine kinase inhibitors |
| UA71945C2 (en) * | 1999-01-27 | 2005-01-17 | Pfizer Prod Inc | Substituted bicyclic derivatives being used as anticancer agents |
| JP3270834B2 (ja) * | 1999-01-27 | 2002-04-02 | ファイザー・プロダクツ・インク | 抗がん剤として有用なヘテロ芳香族二環式誘導体 |
| EE05345B1 (et) * | 1999-02-10 | 2010-10-15 | Astrazeneca Ab | Kinasoliini derivaadid angiogeneesi inhibiitoritena |
| US6080747A (en) * | 1999-03-05 | 2000-06-27 | Hughes Institute | JAK-3 inhibitors for treating allergic disorders |
| UA73993C2 (uk) * | 2000-06-06 | 2005-10-17 | Астразенека Аб | Хіназолінові похідні для лікування пухлин та фармацевтична композиція |
| HN2002000067A (es) * | 2001-03-23 | 2003-10-24 | Bayer Healthcare Llc | Inhibidores de la rho - quinasa. |
| RU2004116911A (ru) * | 2001-11-03 | 2005-11-10 | Астразенека Аб (Se) | Производные хиназолина в качестве противоопухолевых средств |
| GB0126433D0 (en) * | 2001-11-03 | 2002-01-02 | Astrazeneca Ab | Compounds |
| GB0128108D0 (en) * | 2001-11-23 | 2002-01-16 | Astrazeneca Ab | Therapeutic use |
| EP1465900B1 (de) * | 2002-01-10 | 2008-05-14 | Bayer HealthCare AG | Rho-kinase inhibitoren |
| CA2473910C (en) * | 2002-01-23 | 2011-03-15 | Bayer Pharmaceuticals Corporation | Pyrimidine derivatives as rho-kinase inhibitors |
| DE602004014347D1 (de) * | 2003-03-12 | 2008-07-24 | Millennium Pharm Inc | Chinazolin-derivate als tgf-beta-inhibitoren |
-
2002
- 2002-03-22 PE PE2002000225A patent/PE20020958A1/es not_active Application Discontinuation
- 2002-03-22 MY MYPI20021019A patent/MY142915A/en unknown
- 2002-03-22 JP JP2002576235A patent/JP4320705B2/ja not_active Expired - Fee Related
- 2002-03-22 WO PCT/US2002/008660 patent/WO2002076977A2/en not_active Ceased
- 2002-03-22 CA CA2441501A patent/CA2441501C/en not_active Expired - Fee Related
- 2002-03-22 UY UY27225A patent/UY27225A1/es unknown
- 2002-03-22 AU AU2002245709A patent/AU2002245709A1/en not_active Abandoned
- 2002-03-22 AR ARP020101070A patent/AR035792A1/es active IP Right Grant
- 2002-03-22 EP EP02713884A patent/EP1370552B1/de not_active Expired - Lifetime
- 2002-03-22 ES ES02713884T patent/ES2280517T3/es not_active Expired - Lifetime
- 2002-03-22 US US10/103,565 patent/US20030087919A1/en not_active Abandoned
- 2002-03-22 PT PT02713884T patent/PT1370552E/pt unknown
- 2002-03-22 TW TW091105577A patent/TWI336328B/zh not_active IP Right Cessation
- 2002-03-22 MX MXPA03008659A patent/MXPA03008659A/es active IP Right Grant
- 2002-03-22 AT AT02713884T patent/ATE353889T1/de active
- 2002-03-22 DK DK02713884T patent/DK1370552T3/da active
- 2002-03-22 DE DE60218138T patent/DE60218138T2/de not_active Expired - Lifetime
-
2006
- 2006-02-16 US US11/354,978 patent/US20060142314A1/en not_active Abandoned
-
2007
- 2007-04-19 CY CY20071100536T patent/CY1108041T1/el unknown
-
2010
- 2010-03-18 US US12/726,660 patent/US20100249159A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| PT1370552E (pt) | 2007-04-30 |
| WO2002076977A2 (en) | 2002-10-03 |
| JP2004528314A (ja) | 2004-09-16 |
| UY27225A1 (es) | 2002-10-31 |
| AR035792A1 (es) | 2004-07-14 |
| ES2280517T3 (es) | 2007-09-16 |
| DK1370552T3 (da) | 2007-05-07 |
| EP1370552A2 (de) | 2003-12-17 |
| HK1061029A1 (en) | 2004-09-03 |
| CA2441501C (en) | 2010-09-14 |
| CA2441501A1 (en) | 2002-10-03 |
| WO2002076977A3 (en) | 2002-12-12 |
| CY1108041T1 (el) | 2013-09-04 |
| DE60218138D1 (de) | 2007-03-29 |
| MY142915A (en) | 2011-01-31 |
| US20100249159A1 (en) | 2010-09-30 |
| JP4320705B2 (ja) | 2009-08-26 |
| PE20020958A1 (es) | 2002-11-14 |
| EP1370552B1 (de) | 2007-02-14 |
| MXPA03008659A (es) | 2005-04-08 |
| AU2002245709A1 (en) | 2002-10-08 |
| DE60218138T2 (de) | 2007-09-20 |
| US20060142314A1 (en) | 2006-06-29 |
| US20030087919A1 (en) | 2003-05-08 |
| TWI336328B (en) | 2011-01-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE325795T1 (de) | Rho-kinase inhibitoren | |
| DK1370552T3 (da) | Rho-kinase-inhibitorer | |
| ATE505471T1 (de) | Azaindol-kinaseinhibitoren | |
| IS6968A (is) | Nýir týrósínkínasa tálmar | |
| DE60234125D1 (de) | E inhibitoren | |
| DE60320933D1 (de) | Rho-kinase inhibitoren | |
| NO20041293D0 (no) | Alkyn-aryl-fosfodiesterase-4-inhibitorer | |
| IS7599A (is) | Heterósýklískir kínasatálmar | |
| ATE286049T1 (de) | Pyridazinonaldose reductase inhibitoren | |
| NO20021820L (no) | Tyrosinkinaseinhibitorer | |
| DK1317442T3 (da) | Quinolinonderivater som tyrosinkinaseinhibitorer | |
| ATE452891T1 (de) | Pyrimidopyrimidone als kinaseinhibitoren | |
| EP1161433A4 (de) | Tyrosin-kinase-inhibitoren | |
| DE60129794D1 (de) | Pyrrol substituierte indolin-2-on protein kinase inhibitoren | |
| NO20021239L (no) | Pteridinoner som kinase-inhibitorer | |
| ATE524441T1 (de) | Vla-4-inhibitoren | |
| NO20041887L (no) | Benzomidazoler anvendelige som proteinkinase-inhibitorer | |
| DK1272488T3 (da) | Tri-aryl-substitueret ethan-PDE4-inhibitorer | |
| BR0207810A (pt) | inibidores de deformilase de peptìdeo | |
| NO20032807L (no) | Substituerte 8-arylkinolin-fosfodiesterase-4-inhibitorer | |
| EP1570847A4 (de) | Phosphodiesterase 10a-hemmer | |
| EP1670422A4 (de) | Identifizierung von kinase-inhibitoren | |
| EP1651209A4 (de) | Tyrosin-kinase-hemmer | |
| AR028075A1 (es) | Inhibidores de la peptido-desformilasa | |
| NO20002870L (no) | MYT1 kinase inhibitorer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1370552 Country of ref document: EP |